Related Experiment Videos
Hepatitis C: natural history, diagnosis, and management
1Clinical Grants, Professional Services, Amgen Inc., Thousand Oaks, CA 91320, USA. nlam@amgen.com
Insights
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and liver transplants in the US. Current treatments offer limited success, necessitating research into novel therapies.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C infection is a primary cause of chronic viral hepatitis and liver transplantation in the United States.
- Hepatitis C virus (HCV) has six genotypes, with genotype 1 being most common in the US.
- Percutaneous exposure is the primary transmission route for HCV.
Purpose of the Study:
- To review the virology, epidemiology, clinical presentation, diagnosis, and management of hepatitis C.
- To discuss current treatment strategies and emerging therapies for chronic hepatitis C.
- To highlight the need for improved treatment options.
Main Methods:
- Review of existing literature on hepatitis C.
- Analysis of diagnostic methods including antibody testing and HCV RNA detection.
- Evaluation of current treatment regimens (interferon alfa, ribavirin) and their response rates.
Main Results:
- Current treatments (interferon alfa +/- ribavirin) yield sustained virological response rates of 20-40%.
- Response rates are lower for genotype 1, high viral load, and cirrhosis.
- Retreatment strategies are recommended for relapsed patients.
Conclusions:
- Hepatitis C management requires optimized existing strategies and development of new therapies.
- Combination therapies show promise for improved treatment outcomes.
- Further research is essential for more effective hepatitis C treatments.
Abstract:
The virology, epidemiology, clinical spectrum, diagnosis, and management of hepatitis C are reviewed. Hepatitis C infection is responsible for most cases of chronic viral hepatitis in the United States and is the major reason for liver transplantation. Hepatitis C virus (HCV) is divided into six major genotypes, with type 1 being the most prevalent in the United States. Direct percutaneous exposure is the main route of HCV transmission. Diagnosis of the infection is made by HCV antibody testing or direct detection of HCV RNA in serum. Liver biopsy is recommended for evaluating disease severity before treatment is started. The currently approved treatment for patients with chronic hepatitis C who have elevated liver transaminases and compensated liver disease consists of interferon alfa alone or in combination with ribavirin. Rates of sustained biochemical and virological responses in the range of 20-40% have been reported for a 12-month regimen of interferon alfa. Combination therapy with ribavirin improves these rates. Response rates are lower in patients with HCV genotype 1, a serum HCV RNA concentration higher than 1 million copies/mL, and cirrhosis. In patients who relapse after an initial response to interferon alfa, retreatment with interferon alfa plus ribavirin or with a higher dosage of interferon alfa is recommended. New agents under development for use against hepatitis C include viral enzyme inhibitors, ribozymes and antisense oligonucleotides, and immunomodulators. Further research is needed to optimize existing strategies for treating hepatitis C and to develop new, more effective therapies. Ultimately, combination therapies may hold the key.